Search results for "PSMA"

showing 2 items of 22 documents

1,4 dihidropiridinski derivati povećavaju ekspresiju gena Psma3, Psmb5 i Psmc6 u glasničkoj RNA štakora

2021

The ubiquitin-proteasome system modifies different cellular and protein functions. Its dysregulation may lead to disrupted proteostasis associated with multiple pathologies and aging. Pharmacological regulation of proteasome functions is already an important part of the treatment of several diseases. 1,4-dihydropyridine (1,4-DHP) derivatives possess different pharmacological activities, including antiaging and neuroprotective. The aim of this study was to investigate the effects of several 1,4-DHP derivatives on mRNA expression levels of proteasomal genes Psma3, Psmb5, and Psmc6 in several organs of rats. Rats were treated with metcarbatone, etcarbatone, glutapyrone, styrylcarbatone, AV-153…

glutapironDihydropyridinesProteasome Endopeptidase Complexetcarbatoneporemećena proteasomska funkcijaimpaired proteasomal functionsproteasome subunitsToxicologyPSMA3metkarbatonKidneyNeuroprotectionPSMC6glutapyroneAV-153-NaAV-153-Ca; AV-153-Na; etcarbatone; gene expression; glutapyrone; impaired proteasomal functions; metcarbatone; pharmacological activities; proteasome subunits; styrylcarbatone; ubiquitin-proteasome systemAV-153-Ca; AV-153-Na; etkarbaton; glutapiron; metkarbaton; stirilkarbaton; poremećena proteasomska funkcija; proteasomske podjedinice; ubikvitin-proteasomski sustavGene expressionAnimalsstyrylcarbatoneRNA MessengerGeneChemistryPublic Health Environmental and Occupational HealthPSMB5Cell biologyproteasomske podjediniceRatsProteostasisProteasomeubikvitin-proteasomski sustavstirilkarbatongene expressionOriginal Articlepharmacological activitiesAV-153-Caubiquitin-proteasome systemmetcarbatoneetkarbatonArchives of Industrial Hygiene and Toxicology
researchProduct

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

radioligand therapy; PSMA; FDG; PET/CT; mismatch; metastatic castration-resistant prostate cancerCancer Researchmedicine.medical_specialtyFDGPET/CTUrology610Diseaseurologic and male genital diseasesMetastasisProstate cancerPSMAmedicineRC254-282Membrane antigenPET-CTbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPet imagingMetabolic tumor volumemedicine.diseaseradioligand therapyTotal lesion glycolysismetastatic castration-resistant prostate cancerOncologybusinessmismatchCancers
researchProduct